Personalizing health care-is this the right time for warfarin?

Journal of General Internal Medicine

Volumn 24, Issue 5, 2009, Pages 690-691

  Ansell, Jack ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Anticoagulant therapy; Genetic testing; Pharmacogenetics; Warfarin

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; WARFARIN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG METABOLISM; EDITORIAL; GENE MUTATION; GENETIC VARIABILITY; HEALTH CARE; HEALTH PRACTITIONER; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACOGENETICS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; HEALTH CARE DELIVERY; TIME; TRENDS;

DELIVERY OF HEALTH CARE; HUMANS; PHARMACOGENETICS; TIME FACTORS; WARFARIN;

EID: 67349096280     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-009-0951-7     Document Type: Editorial

References (16)

1. BF Gage LJ Lesko 2008 Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues J Thromb Thrombolysis. 25 45 51
2. http://packageinserts.bms.com/pi/pi-coumadin.pdf
3. R Weinshilboum 2003 Inheritance and drug response N Engl J Med. 348 529 537 (Pubitemid 36159889)
4. JL Mega SL Close SD Wivott 2009 Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med. 360 354 362
5. JJ Yang C Cheng W Yang 2009 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia JAMA. 301 393 403
6. J Ansell J Hirsh E Hylek A Jacobson M Crowther G Palareti 2008 The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines Chest. 133 160S 198S
7. www.warfarindosing.org
8. M Beinema RBJ Brouwers T Schalekamp B Wilffert 2008 Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon Thromb Haemost. 100 1052 1057
9. T Li CY Chang DY Jin 2004 Identification of the gene for vitamin K epoxide reductase Nature. 427 541 544 (Pubitemid 38209111)
10. MJ Rieder AP Reiner FB Gage 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med. 352 2285 2293 (Pubitemid 40740552)
11. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009.
12. MH Eckman J Rosand SM Greenberg BF Gage 2009 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation Ann Intern Med. 150 73 83
13. Eckman MH, Greenberg SM, Rosand J. Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med. 2009.
14. JHS You FWH Chan RSM Wong G Cheng 2004 The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis Thromb Haemost. 92 590 597 (Pubitemid 39248016)
15. International Warfarin Pharmacogenetics Consortium 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med. 360 753 764
16. Clinicaltrials.gov identifier: NCT00839657